TWOU, EYPT and CHRS are among after hour mover
Seeking Alpha · 03/03 23:32
Kiniksa Pharmaceuticals, Ltd. (KNSA) Beats Q4 Earnings and Revenue Estimates
NASDAQ · 02/28 16:25
BRIEF-Absci Expands In Europe With Launch Of New Innovation Center
Reuters · 02/28 13:59
FSLY, BTBT and AFMD are among pre market gainers
Seeking Alpha · 02/13 13:22
AbSci (ABSI) Receives a Buy from Berenberg Bank
TipRanks · 02/09 17:45
Absci, St. John's Cancer Institute to Collaborate on Cancer Therapies
Absci, St. John's Cancer Institute to Collaborate on Cancer Therapies
MT Newswires · 02/09 11:13
BRIEF-Absci Deepens Scientific Advisory Board To Accelerate Generative AI Drug Creation
Reuters · 02/08 13:15
Absci Deepens Scientific Advisory Board 'To Accelerate Generative AI Drug Creation'
Benzinga · 02/08 13:03
MNPR and NXL among healthcare movers
Seeking Alpha · 01/23 15:12
BLCM, NVVE and BYSI among mid-day movers
Seeking Alpha · 01/19 18:12
Absci to Participate in the Berenberg Discover AI Seminar
VANCOUVER, Wash. and NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming Berenberg Discover AI Seminar in New York, NY. Absci...
GlobeNewswire · 11/23/2022 13:00
BRIEF-Absci Corp Third Quarter Revenue $2.4 Million
Reuters · 11/09/2022 15:50
Absci reports $27M loss but strong holdings
The company continued to lose money but its CEO says it has enough cash to sustain it through the end of 2025.
American City Business Journals · 11/09/2022 15:47
Absci Corporation (ABSI) Reports Q3 Loss, Tops Revenue Estimates
Absci Corporation (ABSI) delivered earnings and revenue surprises of -11.11% and 32.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/09/2022 14:15
Absci GAAP EPS of -$0.30 misses by $0.02, revenue of $2.37M beats by $0.5M
Seekingalpha · 11/09/2022 13:46
Absci Q3 EPS $(0.30) Up From $(0.33) YoY, Sales $2.37M Up From $1.54M YoY
Benzinga · 11/09/2022 13:15
Absci Reports Third Quarter 2022 Financial Results
Milestone achievement and progress continues in previously announced Merck collaboration Further strengthened executive leadership and Board of Directors VANCOUVER, Wash. and NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a g...
GlobeNewswire · 11/09/2022 13:00
-- Earnings Flash (ABSI) ABSCI CORPORATION Reports Q3 Revenue $2.4M
-- Earnings Flash (ABSI) ABSCI CORPORATION Reports Q3 Revenue $2.4M
MT Newswires · 11/09/2022 08:11
BRIEF-Absci Welcomes Meta Senior Executive To Board Of Directors
Reuters · 11/02/2022 12:30
Institutional owners may consider drastic measures as Absci Corporation's (NASDAQ:ABSI) recent US$46m drop adds to long-term losses
If you want to know who really controls Absci Corporation ( NASDAQ:ABSI ), then you'll have to look at the makeup of...
Simply Wall St. · 09/28/2022 10:44
Webull provides a variety of real-time ABSI stock news. You can receive the latest news about Absci Corp through multiple platforms. This information may help you make smarter investment decisions.
About ABSI
Absci Corporation is a generative artificial intelligence (AI) drug creation company. The Company combines AI with scalable wet lab technologies to create biologics for patients. It has built an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The Company uses its platform to predict, identify, design, construct, screen, select and scale production of biologic drug candidates for its partners, and learn from the data it generates. Its SoluPro technology is a multiplex synthetic biology approach that overcomes the limitations of highest-throughput automation labs. The Company supports its generative AI designs with its wet lab's high-throughput functional validation capabilities. The Company applies generative AI to design optimal drug candidates based on target affinity, safety, manufacturability, and other traits.